Compare H2O America (HTO) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Johnson & Johnson — how do they compare? H2O America trades at $58.54 (market cap $2.43B), while Johnson & Johnson trades at $261.44 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 254.4× H2O America's market cap, and H2O America pays the higher dividend (3.03%). Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Johnson & Johnson for 129 Days on average.
| HTO | JNJ | |
|---|---|---|
Market Cap | $2.43B | $618.09B |
Volume | 593,883 | 6,050,983 |
Sector | Utilities | Health |
52-Week High | $65.43 | $278.43 |
52-Week Low | $44.44 | $186.00 |
Typical Hold Time | 40 Days | 129 Days |
Enterprise Value | $4.22B | $646.37B |
Dividend Yield | 3.03% | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.70, up 1.24% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains strong profitability with 12.91% net margins and recently completed the Quadvest acquisition through its Texas subsidiary. Analyst consensus remains strongly bullish with 83% buy ratings and a $66.50 price target, representing 13% upside potential from current levels.
The outlook appears favorable given the strategic acquisitions and Dividend King status, though execution risks from recent equity dilution and negative cash flow from investing activities warrant monitoring. The stock offers value with reasonable P/E of 20.45 and consistent earnings beats, supported by institutional accumulation including BlackRock's significant position.
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
